TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19084453

Group type: EXPERIMENTAL
Intervention: Inactivated trivalent split virus influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16968577

Group type: EXPERIMENTAL
Intervention: Fixed combination of travoprost 0.004%/timolol 0.5% (T/T)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed combination of latanoprost 0.005%/timolol 0.5% (L/T)
Number of subjects: 0
Study: 15519437

Group type: EXPERIMENTAL
Intervention: Webster-Stratton parenting program (16-hour weekly intervention)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (4-month wait list)
Number of subjects: 26
Study: 11049793

Group type: EXPERIMENTAL
Intervention: Paromomycin (500 mg 4 times daily for 21 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Paromomycin (500 mg q.i.d. for an additional 21 days)
Number of subjects: 35
Study: 9486031

Group type: EXPERIMENTAL
Intervention: Bilateral peripheral iridectomy (PI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bilateral Nd:YAG laser iridotomy (YAG PI)
Number of subjects: 48
Study: 7933789

Group type: EXPERIMENTAL
Intervention: Acebutolol, 400-800 mg/day for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol, 80-160 mg/day for 12 weeks
Number of subjects: 0
Study: 3739795

Group type: EXPERIMENTAL
Intervention: Multicomponent smoking relapse prevention treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic broad-spectrum stop-smoking program plus discussion control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic broad-spectrum stop-smoking program alone
Number of subjects: 0
Study: 30448901

Group type: EXPERIMENTAL
Intervention: Solubilized eggshell membrane (S-ESM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gel with 20% type III/80% type I collagen
Number of subjects: 0
Study: 29606694

Group type: EXPERIMENTAL
Intervention: MoGro mobile grocery program providing access to subsidized healthy foods and complementary events (fitness activities and cooking classes)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MoGro mobile grocery program
Number of subjects: 0
Study: 27094871

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (50,000 units per week)
Number of subjects: 210
Study: 24667381

Group type: EXPERIMENTAL
Intervention: GLP-1 analogue liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22645201

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 6 months
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (healthy prepubertal children)
Number of subjects: 36
Study: 19960352

Group type: EXPERIMENTAL
Intervention: Continuous Exercise at 80% of Maximal Aerobic Speed (CE80)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intermittent Exercise at 110% of Maximal Aerobic Speed (IE110)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continuous Exercise at 60% of Maximal Aerobic Speed (CE60)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intermittent Exercise at 90% of Maximal Aerobic Speed (IE90)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continuous Exercise at 70% of Maximal Aerobic Speed (CE70)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intermittent Exercise at 100% of Maximal Aerobic Speed (IE100)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Continuous Exercise (CE)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mean Heart Rate (HR) during CE and IE
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: CE80 versus IE110 association
Number of subjects: 14
Study: 16458133

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 325 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg/day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of ASA and clopidogrel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Aspirin (ASA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 60
Study: 15100915

Group type: EXPERIMENTAL
Intervention: Out-patient rehabilitation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: In-patient rehabilitation
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Out-patient rehabilitation (but received in-patient treatment)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Overall rehabilitation
Number of subjects: 53
Study: 11399219

Group type: EXPERIMENTAL
Intervention: Callback counselling
Number of subjects: 998

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 998
Study: 9416637

Group type: EXPERIMENTAL
Intervention: Immediate rating condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed rating condition
Number of subjects: 0
Study: 7507201

Group type: EXPERIMENTAL
Intervention: Single dose aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 2879872

Group type: EXPERIMENTAL
Intervention: 200 mg norfloxacin
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: 400 mg norfloxacin
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: TMP-SMZ (160 mg/800 mg)
Number of subjects: 886

Group type: COMPARATOR
Intervention: norfloxacin
Number of subjects: 886

Group type: COMPARATOR
Intervention: TMP-SMZ
Number of subjects: 886
Study: 29847251

Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 424
Study: 27283946

Group type: COMPARATOR
Intervention: SYN-004 (75-750 mg single dose)
Number of subjects: 64

Group type: COMPARATOR
Intervention: SYN-004 (75-300 mg multiple doses every 6 hours for 7 days)
Number of subjects: 64
Study: 24785002

Group type: EXPERIMENTAL
Intervention: Stress group (exposed to a standardized psychosocial stress test - TSST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonstress group (not exposed to stress)
Number of subjects: 48
Study: 22126338

Group type: EXPERIMENTAL
Intervention: Garlic extract for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nystatin for 4 weeks
Number of subjects: 40
Study: 20023707

Group type: EXPERIMENTAL
Intervention: Early immunization (3 months) with 7-valent pneumococcal vaccine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Late immunization (9 months) with 7-valent pneumococcal vaccine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Assessment of anti-pneumococcal antibodies functionality through opsonophagocytic assay
Number of subjects: 28
Study: 18554465

Group type: EXPERIMENTAL
Intervention: Adult gastroscope
Number of subjects: 103

Group type: COMPARATOR
Intervention: Adult colonoscope
Number of subjects: 103
Study: 15703253

Group type: EXPERIMENTAL
Intervention: Post-training sleep (after a night of sleep)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Post-training without intervening sleep (1 hour post-training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlations between behavioral performance and brain activation after sleep
Number of subjects: 0
Study: 12923723

Group type: EXPERIMENTAL
Intervention: Corticosteroids and cytotoxic agents (alternating schedule for 6 months)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Corticosteroids and cytotoxic agents
Number of subjects: 174
Study: 10940699

Group type: EXPERIMENTAL
Intervention: CLAP
Number of subjects: 38

Group type: COMPARATOR
Intervention: VLAP
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both CLAP and VLAP
Number of subjects: 38
Study: 9299907

Group type: EXPERIMENTAL
Intervention: Cycling exercise at 70% VO2max
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonexercise control
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cycling exercise at 55% VO2max
Number of subjects: 20
Study: 8299437

Group type: EXPERIMENTAL
Intervention: Jet-injected insulin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Needle-injected insulin
Number of subjects: 20
Study: 3105477

Group type: EXPERIMENTAL
Intervention: Group P (pancuronium bromide and Metubine sulfate with sedation)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Group S (allowed to shiver)
Number of subjects: 33
Study: 16169887

Group type: EXPERIMENTAL
Intervention: Digital mammography
Number of subjects: 42760

Group type: COMPARATOR
Intervention: Film mammography
Number of subjects: 42760
Study: 16394080

Group type: EXPERIMENTAL
Intervention: GHD group (untreated isolated GHD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HET group (heterozygous for GHRHR mutation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CO group (homozygous for wild-type allele)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: GHD group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HET group
Number of subjects: 60

Group type: COMPARATOR
Intervention: CO group
Number of subjects: 60
Study: 16400382

Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiotherapy (RTx) in addition to standard therapy
Number of subjects: 273

Group type: COMPARATOR
Intervention: Standard therapy (thyroidectomy, ablative radioiodine therapy, and diagnostic 131I whole-body scintigraphy)
Number of subjects: 273
Study: 16449618

Group type: EXPERIMENTAL
Intervention: Nonmyeloablative hematopoietic stem cell transplantation (HSCT)
Number of subjects: 50
Study: 16489696

Group type: COMPARATOR
Intervention: Conventional fractionation (66-70 Gy in 6(1/2)-7 weeks, 2 Gy per fraction a day, 5 fractions a week)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiotherapy (74.4-79.2 Gy in 6.2-7 weeks, 1.2 Gy per fraction twice a day)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation with concomitant boost (68.7-72 Gy in 6 weeks, 1.8 Gy per fraction a day and 1.5 Gy per fraction a day for boost)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: All treatment groups (Conventional, Hyperfractionated, Accelerated)
Number of subjects: 152
Study: 16522693

Group type: EXPERIMENTAL
Intervention: GH naive adult dwarfs with severe IGHD
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 22
Study: 16531613

Group type: EXPERIMENTAL
Intervention: Active treatment with 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12
Number of subjects: 5522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522

Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 5522
Study: 16551963

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 21
Study: 16554525

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (239 patients) at a maximal daily dose of 400 mg
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Sertraline (238 patients) at a maximal daily dose of 200 mg
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Extended-release venlafaxine (250 patients) at a maximal daily dose of 375 mg
Number of subjects: 727
Study: 16554526

Group type: EXPERIMENTAL
Intervention: Sustained-release bupropion (up to 400 mg per day)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Buspirone (up to 60 mg per day)
Number of subjects: 565
Study: 16554527

Group type: EXPERIMENTAL
Intervention: ACAT inhibitor pactimibe (100 mg per day)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 408
Study: 16563165

Group type: EXPERIMENTAL
Intervention: Weekly pediatric evaluation and referral to appropriate care for infants with cleft lip and/or palate.
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: Pediatric evaluations every three months for intervened cases.
Number of subjects: 696

Group type: COMPARATOR
Intervention: Non-intervened cases matched and compared to healthy controls.
Number of subjects: 696
Study: 16628299

Group type: EXPERIMENTAL
Intervention: Parenteral penicillin or oral amoxicillin (WHO standard treatment)
Number of subjects: 523
Study: 16681848

Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux) plus intensity-modulated radiation therapy (IMRT)
Number of subjects: 30
Study: 16689987

Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-surgical treatment
Number of subjects: 0
Study: 16709929

Group type: EXPERIMENTAL
Intervention: pegylated interferon alpha-2a
Number of subjects: 27
Study: 16714187

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (30-325 mg daily + 200 mg twice daily)
Number of subjects: 2739

Group type: COMPARATOR
Intervention: Aspirin alone (30-325 mg daily)
Number of subjects: 2739

Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 2739
Study: 16756656

Group type: EXPERIMENTAL
Intervention: Eccentric strengthening intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concentric strengthening intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orthoses alone
Number of subjects: 0
Study: 16757724

Group type: EXPERIMENTAL
Intervention: Sunitinib, 50 mg per day given orally for 4 consecutive weeks followed by 2 weeks off per treatment cycle.
Number of subjects: 106
Study: 16758521

Group type: EXPERIMENTAL
Intervention: Epoetin product E1 in trial T1
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Epoetin product E2 in trial T2
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Epoetin product E2 in trial T2 (adjusted)
Number of subjects: 44
Study: 16764734

Group type: EXPERIMENTAL
Intervention: Tailored educational intervention for GPs including educational outreach visits, workshops, audit and feedback.
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group receiving no intervention towards prescription patterns in elderly, but educational intervention for antibiotics.
Number of subjects: 600
Study: 16775234

Group type: EXPERIMENTAL
Intervention: Dasatinib (15 to 240 mg per day) administered orally in four-week treatment cycles, once or twice daily.
Number of subjects: 84
Study: 16775235

Group type: EXPERIMENTAL
Intervention: Nilotinib (AMN107) at various doses (50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1200 mg once daily; 400 mg and 600 mg twice daily)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Nilotinib (AMN107)
Number of subjects: 119
Study: 16776824

Group type: EXPERIMENTAL
Intervention: Educational outreach visits, workshops, audit and feedback conducted by trained GPs (Rx-PADs).
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 80
Study: 16781217

Group type: EXPERIMENTAL
Intervention: Fludrocortisone 0.05 to 0.2 mg
Number of subjects: 310

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 310
Study: 16794899

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 16831964

Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride, 12 mg/m2, administered monthly via intravenous infusion for 6 months followed by 3 additional treatments every 3 months
Number of subjects: 5
Study: 16836672

Group type: EXPERIMENTAL
Intervention: Guidant VITALITY 2 family ICD with Rhythm ID
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Medtronic ICD using Enhanced PR Logic or Wavelet discrimination algorithms
Number of subjects: 2000
Study: 16837679

Group type: EXPERIMENTAL
Intervention: Doppler ultrasonography of the middle cerebral artery
Number of subjects: 165

Group type: COMPARATOR
Intervention: Amniotic-fluid DeltaOD450
Number of subjects: 165
Study: 16855264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3548

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3548

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 3548

Group type: EXPERIMENTAL
Intervention: Risk-conferring genotypes in TCF7L2
Number of subjects: 3548
Study: 16864722

Group type: EXPERIMENTAL
Intervention: Fibrinogen (measured with immunoassay)
Number of subjects: 27742

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (hs-CRP)
Number of subjects: 27742

Group type: EXPERIMENTAL
Intervention: Fibrinogen and hs-CRP combined
Number of subjects: 27742

Group type: EXPERIMENTAL
Intervention: Fibrinogen (top quintile)
Number of subjects: 27742

Group type: EXPERIMENTAL
Intervention: hs-CRP (top quintile)
Number of subjects: 27742
Study: 16864730

Group type: COMPARATOR
Intervention: Norepinephrine infusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Norepinephrine infusion after endotoxin administration
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: K-channel blocker tetraethylammonium (TEA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: NO synthase inhibitor N(G)-monomethyl-l-arginine (L-NMMA)
Number of subjects: 30
Study: 16875985

Group type: EXPERIMENTAL
Intervention: Ranolazine (1000 mg twice a day for 6 weeks)
Number of subjects: 565

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 565
Study: 16880310

Group type: EXPERIMENTAL
Intervention: No touch approach to diagnostic hysteroscopy without anesthesia
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional diagnostic hysteroscopy with 10 mL of 3% mepivacaine hydrochloride
Number of subjects: 130
Study: 16880313

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 15733

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15733

Group type: EXPERIMENTAL
Intervention: Sexual activity in the past year (not married or living as married)
Number of subjects: 15733
Study: 16882711

Group type: EXPERIMENTAL
Intervention: 5-aza-2'-deoxycytidine (decitabine) 15 mg/m² IV daily for 10 days + valproic acid (VPA) escalating doses orally for 10 days (maximum 50 mg/kg daily)
Number of subjects: 54
Study: 16885550

Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 49
Study: 16899778

Group type: EXPERIMENTAL
Intervention: Anakinra (1 to 2 mg per kilogram of body weight per day subcutaneously)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Anakinra withdrawal
Number of subjects: 18
Study: 16901335

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (INH, Exubera)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Subcutaneous (s.c.) insulin and other licensed therapies
Number of subjects: 700
Study: 16905786

Group type: EXPERIMENTAL
Intervention: Atazanavir-ritonavir alone
Number of subjects: 36
Study: 16921041

Group type: EXPERIMENTAL
Intervention: mutKIT in inv(16) AML
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: mutKIT in t(8;21) AML
Number of subjects: 110
Study: 16925569

Group type: EXPERIMENTAL
Intervention: Single-dose rituximab
Number of subjects: 49
Study: 16943394

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg twice daily
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg once daily
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Combined doses of celecoxib (200 mg twice daily and 400 mg twice daily from APC, and 400 mg once daily from PreSAP)
Number of subjects: 83
Study: 16952304

Group type: EXPERIMENTAL
Intervention: Anti-CCR4 monoclonal antibody (mAb)
Number of subjects: 0
Study: 16959033

Group type: EXPERIMENTAL
Intervention: Candesartan (up to 32 mg/day during 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16962882

Group type: EXPERIMENTAL
Intervention: 30 mg dapoxetine
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: 60 mg dapoxetine
Number of subjects: 2614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2614
Study: 17005949

Group type: EXPERIMENTAL
Intervention: Islet transplantation using the Edmonton protocol
Number of subjects: 36
Study: 17010801

Group type: EXPERIMENTAL
Intervention: Phospholamban R14 deletion mutation
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Identical PLN mutation
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: PLN mutations
Number of subjects: 260
Study: 17012043

Group type: EXPERIMENTAL
Intervention: Risk-adapted craniospinal radiotherapy followed by four cycles of cyclophosphamide-based, dose-intensive chemotherapy
Number of subjects: 134
Study: 17018123

Group type: EXPERIMENTAL
Intervention: Campath-1H (alemtuzumab) induction with sirolimus immunosuppression
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Steroid-free immunosuppressive regimens
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Monotherapy for immunosuppression (12 on sirolimus)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Campath-1H induction
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Campath-1H and sirolimus therapy
Number of subjects: 29
Study: 17021321

Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg for 21 days every 4 weeks or daily)
Number of subjects: 148
Study: 17060336

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (co-trimoxazole) for seven days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo for seven days
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole-trimethoprim (co-trimoxazole)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 17060377

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2022

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2022
Study: 17060544

Group type: EXPERIMENTAL
Intervention: External jugular vein (EJV) examination
Number of subjects: 35

Group type: COMPARATOR
Intervention: Internal jugular vein (control)
Number of subjects: 35
Study: 17070980

Group type: EXPERIMENTAL
Intervention: Automated feedback on CPR
Number of subjects: 284

Group type: COMPARATOR
Intervention: No feedback on CPR
Number of subjects: 284
Study: 17076974

Group type: EXPERIMENTAL
Intervention: Acetaminophen 3.9 g daily
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1950-4000 mg/day
Number of subjects: 1530

Group type: EXPERIMENTAL
Intervention: Acetaminophen treatment
Number of subjects: 1530
Study: 17079762

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment (scaling and root planing before 21 weeks of gestation) with monthly tooth polishing and oral hygiene instruction
Number of subjects: 823

Group type: COMPARATOR
Intervention: Control group (scaling and root planing after delivery)
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal treatment
Number of subjects: 823
Study: 17090650

Group type: EXPERIMENTAL
Intervention: Heptavalent pneumococcal conjugate vaccine (7vPCV), administered in 3 consecutive doses in monthly intervals starting 6 to 9 months after alloHSCT
Number of subjects: 53
Study: 17107609

Group type: EXPERIMENTAL
Intervention: Buprenorphine and Valproate (BPN/VPA)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Clonidine and Carbamazepine (CLN/CBZ)
Number of subjects: 62
Study: 17109179

Group type: EXPERIMENTAL
Intervention: Wide excision as initial therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Wide excision as salvage therapy
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: No neoadjuvant or adjuvant therapy
Number of subjects: 12